CV Ranexa Testicular Safety Issue Resolved, Firm Says; QT Issue “Receding”
Executive Summary
CV Therapeutics believes that it can resolve FDA's questions about potential testicular toxicity associated with the pending chronic angina therapy Ranexa (ranolazine) in the "short term.
You may also be interested in...
CV Therapeutics May Launch Ranexa In 2006, Hopes For Expanded Label
CV Therapeutics is planning for a potential 2006 launch for its pending chronic angina therapy Ranexa
CV Therapeutics May Launch Ranexa In 2006, Hopes For Expanded Label
CV Therapeutics is planning for a potential 2006 launch for its pending chronic angina therapy Ranexa
Ranexa Restricted Angina Indication Would Require New Study, Cmte. Says
CV Therapeutics' Ranexa could receive a restricted indication for use in refractory angina patients with a new study in that population, FDA's Cardiovascular & Renal Drugs Advisory Committee said Dec. 9